Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

Highlights from SCAI 2025: Meet the new president | Tirzepatide vs. semaglutide | Cannabis & heart failure | CT-guided PCI

News You Need to Know Today
Highlights from SCAI 2025: Meet the new president | Tirzepatide vs. semaglutide | Cannabis & heart failure | CT-guided PCI
Friday, May 9, 2025
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Highlights from SCAI 2025

New SCAI president lists advocacy, cardiogenic shock among his top priorities

Srihari Naidu, MD, spoke to Cardiovascular Business about his plan to take SCAI in some bold new directions.

READ MORE >
Srihari S. Naidu, MD, FACC, FAHA, MSCAI, assumed the role of president of the Society for Cardiovascular Angiography and Interventions (SCAI) May 3 during the society's annual meeting. He outlined his ambitious plans to take SCAI in some new directions. #SCAI #SCAI2025
Share on Twitter Share on Facebook Share on Linkedin

New SCAI president lists advocacy, cardiogenic shock among his top priorities

Share on Twitter Share on Facebook Share on Linkedin
Srihari S. Naidu, MD, FACC, FAHA, MSCAI, assumed the role of president of the Society for Cardiovascular Angiography and Interventions (SCAI) May 3 during the society's annual meeting. He outlined his ambitious plans to take SCAI in some new directions. #SCAI #SCAI2025
Srihari Naidu, MD, spoke to Cardiovascular Business about his plan to take SCAI in some bold new directions.
READ MORE >

Tirzepatide bests semaglutide in patients with type 2 diabetes, kidney disease and heart failure

Researchers examined data from more than 9,000 patients, sharing their findings at SCAI 2025.

READ MORE >
tirzepatide injections Zepbound Eli Lilly. The U.S. Food and Drug Administration (FDA) cleared Eli Lilly and Company’s tirzepatide injections for chronic weight management in adult patients who are obese, overweight or present with at least one weight-related condition such as high blood pressure or high cholesterol. These weekly injections are being sold and distributed under the brand name Zepbound. Tirzepatide is also used in Mounjaro, FDA cleared in 2022 for improving glycemic control in adults.
Share on Twitter Share on Facebook Share on Linkedin

Tirzepatide bests semaglutide in patients with type 2 diabetes, kidney disease and heart failure

Share on Twitter Share on Facebook Share on Linkedin
tirzepatide injections Zepbound Eli Lilly. The U.S. Food and Drug Administration (FDA) cleared Eli Lilly and Company’s tirzepatide injections for chronic weight management in adult patients who are obese, overweight or present with at least one weight-related condition such as high blood pressure or high cholesterol. These weekly injections are being sold and distributed under the brand name Zepbound. Tirzepatide is also used in Mounjaro, FDA cleared in 2022 for improving glycemic control in adults.
Researchers examined data from more than 9,000 patients, sharing their findings at SCAI 2025.
READ MORE >

A super alternative: BATMAN helps cardiologists limit complications during TMVR

The BATMAN technique is a safe, effective way to prevent LVOT obstruction during high-risk transcatheter mitral valve replacement, according to new data presented at SCAI 2025.

READ MORE >
BATMAN LVOT
Share on Twitter Share on Facebook Share on Linkedin

A super alternative: BATMAN helps cardiologists limit complications during TMVR

Share on Twitter Share on Facebook Share on Linkedin
BATMAN LVOT
The BATMAN technique is a safe, effective way to prevent LVOT obstruction during high-risk transcatheter mitral valve replacement, according to new data presented at SCAI 2025.
READ MORE >

Consistent cannabis use linked to multiple cardiovascular risks for heart failure patients

Cannabis use can be especially harmful for heart failure patients, according to new data presented at SCAI 2025.

READ MORE >
cannabis use disorder marijuana joint weed smoking
Share on Twitter Share on Facebook Share on Linkedin

Consistent cannabis use linked to multiple cardiovascular risks for heart failure patients

Share on Twitter Share on Facebook Share on Linkedin
cannabis use disorder marijuana joint weed smoking
Cannabis use can be especially harmful for heart failure patients, according to new data presented at SCAI 2025.
READ MORE >

‘A defining moment’: How cardiologists can get the most out of CT-guided PCI

SCAI and SCCT have collaborated on a new document designed to get more interventional cardiologists to embrace CT-guided PCI going forward. 

READ MORE >
Carlos Collet, MD, PhD, (center) and colleagues perform CT-guided PCI. Image courtesy of CoreAalst.
Share on Twitter Share on Facebook Share on Linkedin

‘A defining moment’: How cardiologists can get the most out of CT-guided PCI

Share on Twitter Share on Facebook Share on Linkedin
Carlos Collet, MD, PhD, (center) and colleagues perform CT-guided PCI. Image courtesy of CoreAalst.
SCAI and SCCT have collaborated on a new document designed to get more interventional cardiologists to embrace CT-guided PCI going forward. 
READ MORE >

Cardiologists share late-breaking TAVR data on first day of SCAI 2025

New TAVR data on SAPT vs. DAPT and prosthesis-patient mismatch among women were some of the many highlights of the conference's opening day.

READ MORE >
cardiologists heart doctors
Share on Twitter Share on Facebook Share on Linkedin

Cardiologists share late-breaking TAVR data on first day of SCAI 2025

Share on Twitter Share on Facebook Share on Linkedin
cardiologists heart doctors
New TAVR data on SAPT vs. DAPT and prosthesis-patient mismatch among women were some of the many highlights of the conference's opening day.
READ MORE >

Stenting ‘an important treatment option’ for PCI patients with complete blockages

The study's lead author emphasized that stenting during CTO PCI procedures "should be considered safe and effective in the long term."

READ MORE >
heart-stent.jpg
Share on Twitter Share on Facebook Share on Linkedin

Stenting ‘an important treatment option’ for PCI patients with complete blockages

Share on Twitter Share on Facebook Share on Linkedin
heart-stent.jpg
The study's lead author emphasized that stenting during CTO PCI procedures "should be considered safe and effective in the long term."
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

News Alert: CMS proposes major TAVR changes
Cath lab kits recalled | Looking ahead to the future of FFR-CT | Medtronic completes major acquisition
FDA sees potential in heart failure software | SCCT & SCAI take on CT-derived FFR | Predicting long-term stroke risk
Abbott recalls heart monitoring tech | Redo TAVR with balloon-expandable valves | FDA clears new clot-removing device
Week in Review: Star Trek star's family awarded $13M | AI for cardiac amyloidosis | TAVR concerns | New CKM syndrome guidelines
A brand new payment model | Cardiologist compensation keeps rising | Major medtech player invests $1.5B in TAVR tech
Death after TAVR: New data support a change | Rural hospital in spotlight for wrong reason | Heart changes linked to cancer risk

Pagination

    • Current page 1
    • Page 2
    • Page 3
    • Page 4
    • Page 5
    • Page 6
    • Page 7
    • Page 8
    • Page 9 …
    • Next page ››
    • Last page Last »
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
 
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme
Trimed Popup